LOUISVILLE, Ky., Aug. 31, 2021 /PRNewswire/ -- US WorldMeds, a Kentucky-based specialty pharmaceutical company, announced Walgreens will stock LUCEMYRA (lofexidine) tablets in Walgreens pharmacies across the U.S., effective September 1. LUCEMYRA is the only FDA-approved, non-opioid, non-addictive treatment for relief of multiple symptoms of opioid withdrawal in adults and requires a valid prescription to be dispensed.1 Eligible patients covered by commercial insurance will pay $0* for a LUCEMYRA prescription. Patients without insurance coverage for LUCEMYRA may be eligible to pay $300 for a LUCEMYRA prescription.
Bausch Health has yet to fully recover from its tainted past, and a new threat in the form of a rival to its top-seller Xifaxan could pile more pressure on the drugmaker.
Last month, WorldMeds won a historic FDA approval for opioid withdrawal drug Lucemyra, but it needed a marketing partner to help roll it out. Valeant’s Salix has taken the job.
The US FDA has approved US WorldMeds LLC’s non-opioid treatment Lucemyra, adding another “tool to the toolbox” for withdrawal management, says American Society of Addiction Medicine.
Patients who go off opioid painkillers face excruciating withdrawal symptoms such as anxiety, nausea, vomiting, insomnia, muscle aches and more. Now, thanks to an FDA approval for US WorldMeds' Lucemyra, they'll have the first drug designed to fight those symptoms.
The opioid addiction market got a new player Wednesday with the FDA approval of Lucemyra, a pill that helps patients manage symptoms of withdrawal.
On Wednesday, the FDA approved the first drug designed to treat the symptoms of opioid withdrawal, which can be painful and hook users in a potentially deadly cycle of addiction.
US WorldMeds announced that the US Food and Drug Administration (FDA) approved Lucemyra (lofexidine) for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. The FDA reviewed Lucemyra under Priority Review, which is granted to submissions for medications that would provide significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions.
US WorldMeds today announced that the US Food and Drug Administration (FDA) approved LUCEMYRA (lofexidine) for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. The FDA reviewed LUCEMYRA under Priority Review, which is granted to submissions for medications that would provide significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions.